Tislelizumab (Tisle) combined with/without gemcitabine and cisplatin (GC) as adjuvant therapy in patients at high risk after upper urothelial carcinoma (UTUC) surgery: A realworld study

被引：0
|
作者：
Yang, Xiaojian [1 ]
Quan, Penghe [1 ]
Yu, Changjiang [1 ]
机构：
[1] Air Force Mil Med Univ, XIjing Hosp, Xian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16592
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tislelizumab combined with gemcitabine and cisplatin (GC) as adjuvant therapy in patients with high-risk upper urothelial carcinoma (UTUC) after surgery: A 2-year follow-up, real-world study
    Quan, Penghe
    Hou, Haozhong
    Yang, Xiaojian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
    Tan, X.
    Wu, Z.
    Wang, Y.
    Yao, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1560 - S1560
  • [3] A phase II study of tislelizumab(T) as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC)
    Huang, J.
    Cai, X.
    Kong, W.
    Zhang, J.
    Chen, Y.
    Chen, H.
    Xue, W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1556 - S1557
  • [4] Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy
    Gao, Zhimin
    Pang, Yubin
    Qin, Xu
    Li, Gang
    Wang, Zewei
    Zhang, Lei
    Wang, Junqi
    Qi, Nienie
    Li, Hailong
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 592 - 601
  • [5] Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy
    Zhimin Gao
    Yubin Pang
    Xu Qin
    Gang Li
    Zewei Wang
    Lei Zhang
    Junqi Wang
    Nienie Qi
    Hailong Li
    International Journal of Clinical Oncology, 2024, 29 : 592 - 601
  • [6] Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma: A Real-World Study
    Wang, Yanjun
    Zhong, Kaihua
    Tan, Xingliang
    Zhou, Qianghua
    Jiang, Lijuan
    Yao, Kai
    Wu, Zhiming
    CANCER MEDICINE, 2025, 14 (04):
  • [7] A phase II study of tislelizumab (T) monotherapy as neoadjuvant treatment for cisplatin-ineligible high risk upper tract urothelial carcinoma (UTUC).
    Huang, Jiwei
    Cai, Xinyun
    Kong, Wen
    Zhang, Jin
    Chen, Yonghui
    Chen, Haige
    Xue, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 591 - 591
  • [8] Effectiveness of tislelizumab combined with chemotherapy for high recurrence risk patients with upper tract urothelial carcinoma after radical nephroureterectomy
    Zhang, J.
    Chen, Z.
    Zhu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1524 - S1524
  • [9] The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma
    Zhang, Jingwen
    Yang, Meng
    Wei, Dongqun
    Zhang, Deru
    Chen, Zeyu
    Zhu, Haitao
    BMC CANCER, 2024, 24 (01)
  • [10] The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma
    Jingwen Zhang
    Meng Yang
    Dongqun Wei
    Deru Zhang
    Zeyu Chen
    Haitao Zhu
    BMC Cancer, 24
12345